Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

PURPOSE: Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietanza, M. Catherine, Waqar, Saiama N., Krug, Lee M., Dowlati, Afshin, Hann, Christine L., Chiappori, Alberto, Owonikoko, Taofeek K., Woo, Kaitlin M., Cardnell, Robert J., Fujimoto, Junya, Long, Lihong, Diao, Lixia, Wang, Jing, Bensman, Yevgeniva, Hurtado, Brenda, de Groot, Patricia, Sulman, Erik P., Wistuba, Ignacio I., Chen, Alice, Fleisher, Martin, Heymach, John V., Kris, Mark G., Rudin, Charles M., Byers, Lauren Averett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085179/
https://www.ncbi.nlm.nih.gov/pubmed/29906251
http://dx.doi.org/10.1200/JCO.2018.77.7672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085179/
https://www.ncbi.nlm.nih.gov/pubmed/29906251
http://dx.doi.org/10.1200/JCO.2018.77.7672

Ejemplares similares